 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ABELCET increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ABELCET increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ABELCET increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ABELCET increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ABELCET increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ABELCET"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ABELCET: adverse_reactions: ADVERSE REACTIONS The total safety data base is composed of [0m[1;31m921[0m[31m patients treated with ABELCET Â® [0m[1;31m([0m[1;31m5[0m[31m patients were enrolled twice and counted as separate patients[0m[1;31m)[0m[31m, [0m
[31mof whom [0m[1;31m775[0m[31m were treated with [0m[1;31m5[0m[31m mg/kg/day. Of these [0m[1;31m775[0m[31m patients, [0m[1;31m194[0m[31m patients were treated in four comparative studies; [0m[1;31m25[0m[31m were treated in open-label, non-comparative studies; and [0m[1;31m556[0m[31m patients were [0m
[31mtreated in an open-label, emergency-use program. Most had underlying hematologic neoplasms, and many were receiving multiple concomitant medications. Of the [0m[1;31m556[0m[31m patients treated with ABELCET Â® , [0m[1;31m9[0m[31m% [0m
[31mdiscontinued treatment due to adverse events regardless of presumed relationship to study drug. In general, the adverse events most commonly reported with ABELCET Â® were transient chills and/or fever [0m
[31mduring infusion of the drug. ABELCET: adverse_reactions: Adverse Events a with an Incidence of â‰¥[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m Adverse Event Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m of Patients Chills [0m[1;31m18[0m[31m Fever [0m[1;31m14[0m[31m Increased Serum Creatinine [0m[1;31m11[0m[31m [0m
[31mMultiple Organ Failure [0m[1;31m11[0m[31m Nausea [0m[1;31m9[0m[31m Hypotension [0m[1;31m8[0m[31m Respiratory Failure [0m[1;31m8[0m[31m Vomiting [0m[1;31m8[0m[31m Dyspnea [0m[1;31m7[0m[31m Sepsis [0m[1;31m7[0m[31m Diarrhea [0m[1;31m6[0m[31m Headache [0m[1;31m6[0m[31m Cardiac Arrest [0m[1;31m6[0m[31m Hypertension [0m[1;31m5[0m[31m Hypokalemia [0m[1;31m5[0m[31m Infection [0m[1;31m5[0m[31m Kidney Failure [0m[1;31m5[0m[31m [0m
[31mPain [0m[1;31m5[0m[31m Thrombocytopenia [0m[1;31m5[0m[31m Anemia [0m[1;31m4[0m[31m Hyperbilirubinemia [0m[1;31m4[0m[31m Gastrointestinal Hemorrhage [0m[1;31m4[0m[31m Leukopenia [0m[1;31m4[0m[31m Rash [0m[1;31m4[0m[31m Respiratory Disorder [0m[1;31m4[0m[31m Chest Pain [0m[1;31m3[0m[31m Nausea and Vomiting [0m[1;31m3[0m[31m a The causal association between [0m
[31mthese adverse events and ABELCET Â® is uncertain. ABELCET: adverse_reactions: The following adverse events have also been reported in patients using ABELCET Â® in open-label, uncontrolled clinical [0m
[31mstudies. The causal association between these adverse events and ABELCET Â® is uncertain. Body as a whole: malaise, weight loss, deafness, injection site reaction including inflammation Allergic: [0m
[31mbronchospasm, wheezing, asthma, anaphylactoid and other allergic reactions Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction, hemoptysis, tachypnea, thrombophlebitis, [0m
[31mpulmonary embolus, cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation. ABELCET: adverse_reactions: Dermatological: maculopapular rash, pruritus, exfoliative dermatitis, [0m
[31merythema multiforme Gastrointestinal: acute liver failure, hepatitis, jaundice, melena, anorexia, dyspepsia, cramping, epigastric pain, veno-occlusive liver disease, diarrhea, hepatomegaly, [0m
[31mcholangitis, cholecystitis Hematologic: coagulation defects, leukocytosis, blood dyscrasias including eosinophilia Musculoskeletal: myasthenia, including bone, muscle, and joint pains Neurologic: [0m
[31mconvulsions, tinnitus, visual impairment, hearing loss, peripheral neuropathy, transient vertigo, diplopia, encephalopathy, cerebral vascular accident, extrapyramidal syndrome and other neurologic [0m
[31msymptoms Urogenital: oliguria, decreased renal function, anuria, renal tubular acidosis, impotence, dysuria Serum electrolyte ABELCET: adverse_reactions: abnormalities: hypomagnesemia, hyperkalemia, [0m
[31mhypocalcemia, hypercalcemia Liver function test abnormalities: increased AST, ALT, alkaline phosphatase, LDH Renal function test abnormalities: increased BUN Other test abnormalities: acidosis, [0m
[31mhyperamylasemia, hypoglycemia, hyperglycemia, hyperuricemia, hypophosphatemia To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m393[0m[31m-[0m[1;31m4584[0m[31m or by email at [0m
[31mdrugsafety@leadiant.com or contact the FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/safety/medwatch.         [0m
[31mSOUR[0m[1;31mCE:ABE[0m[31mLCET label[0m


[31mCONTENT: ABELCET: geriatric_use: Geriatric Use: Forty-nine elderly patients, age [0m[1;31m65[0m[31m years or over, have been treated with ABELCET Â® at [0m[1;31m5[0m[31m mg/kg/day in two open-label studies and one small, prospective,[0m
[31msingle-arm study. No serious unexpected adverse events have been reported.         [0m
[31mSOUR[0m[1;31mCE:ABE[0m[31mLCET label[0m


[31mCONTENT: ABELCET: drug_interactions: Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications. Skeletal muscle relaxants: Amphotericin [0m
[31mB-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants [0m[1;31m([0m[31me.g., tubocurarine[0m[1;31m)[0m[31m due to hypokalemia. When administered concomitantly with ABELCET Â® , serum potassium levels [0m
[31mshould be closely monitored. Zidovudine: Increased myelotoxicity and nephrotoxicity were observed in dogs when either ABELCET Â® [0m[1;31m([0m[31mat doses [0m[1;31m0.16[0m[31m or [0m[1;31m0.5[0m[31m times the recommended human dose[0m[1;31m)[0m[31m or amphotericin [0m
[31mB desoxycholate [0m[1;31m([0m[31mat [0m[1;31m0.5[0m[31m times the recommended human dose[0m[1;31m)[0m[31m were administered concomitantly with zidovudine for [0m[1;31m30[0m[31m days. If zidovudine is used concomitantly with ABELCET Â® , renal and hematologic [0m
[31mfunction should be closely monitored. ABELCET: precautions: Carcinogenesis, Mutagenesis, and Impairment of Fertility: No long-term studies in animals have been performed to evaluate the carcinogenic [0m
[31mpotential of ABELCET Â® . The following in vitro [0m[1;31m([0m[31mwith and without metabolic activation[0m[1;31m)[0m[31m and in vivo studies to assess ABELCET Â® for mutagenic potential were conducted: bacterial reverse mutation [0m
[31massay, mouse lymphoma forward mutation assay, chromosomal aberration assay in CHO cells, and in vivo mouse micronucleus assay. ABELCET Â® was found to be without mutagenic effects in all assay systems.[0m
[31mStudies demonstrated that ABELCET Â® had no impact on fertility in male and female rats at doses up to [0m[1;31m0.32[0m[31m times the recommended human dose [0m[1;31m([0m[31mbased on body surface area considerations[0m[1;31m)[0m[31m. Pregnancy: [0m
[31mThere are no reports of pregnant women having been treated with ABELCET Â® . Teratogenic Effects. ABELCET: precautions: Reproductive studies in rats and rabbits at doses of ABELCET Â® up to [0m[1;31m0.64[0m[31m times [0m
[31mthe human dose revealed no harm to the fetus. Because animal reproductive studies are not always predictive of human response, and adequate and well-controlled studies have not been conducted in [0m
[31mpregnant women, ABELCET Â® should be used during pregnancy only after taking into account the importance of the drug to the mother. Nursing Mothers: It is not known whether ABELCET Â® is excreted in [0m
[31mhuman milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in breast-fed infants from ABELCET Â® , a decision should be made whether to [0m
[31mdiscontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. ABELCET: precautions: Pediatric Use: One hundred eleven children [0m[1;31m([0m[1;31m2[0m[31m were enrolled twice [0m
[31mand counted as separate patients[0m[1;31m)[0m[31m, age [0m[1;31m16[0m[31m years and under, of whom [0m[1;31m11[0m[31m were less than [0m[1;31m1[0m[31m year, have been treated with ABELCET Â® at [0m[1;31m5[0m[31m mg/kg/day in two open-label studies and one small, prospective, [0m
[31msingle-arm study. In one single-center study, [0m[1;31m5[0m[31m children with hepatosplenic candidiasis were effectively treated with [0m[1;31m2.5[0m[31m mg/kg/day of ABELCET Â® . No serious unexpected adverse events have been [0m
[31mreported. Geriatric Use: Forty-nine elderly patients, age [0m[1;31m65[0m[31m years or over, have been treated with ABELCET Â® at [0m[1;31m5[0m[31m mg/kg/day in two open-label studies and one small, prospective, single-arm study. No [0m
[31mserious unexpected adverse events have been reported.         [0m
[31mSOUR[0m[1;31mCE:ABE[0m[31mLCET label[0m


[31mCONTENT: ABELCET: pregnancy: Pregnancy: There are no reports of pregnant women having been treated with ABELCET Â® . Teratogenic Effects. Reproductive studies in rats and rabbits at doses of ABELCET Â® [0m
[31mup to [0m[1;31m0.64[0m[31m times the human dose revealed no harm to the fetus. Because animal reproductive studies are not always predictive of human response, and adequate and well-controlled studies have not been [0m
[31mconducted in pregnant women, ABELCET Â® should be used during pregnancy only after taking into account the importance of the drug to the mother.         [0m
[31mSOUR[0m[1;31mCE:ABE[0m[31mLCET label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: ABELCET has been reported to have myocardial infarction as an adverse event in patients using the drug in open-label, uncontrolled clinical studies. However, the causal association between [0m
[32mthese adverse events and ABELCET is uncertain.[0m

[32mSOURCE: ABELCET label[0m
[32mEXTRACT_START_END: Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction[0m[32m...[0m[32m cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation.[0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: ABELCET has been reported to have myocardial infarction as [0m
[34man adverse event in patients using the drug in open-label, uncontrolled clinical studies. However, the causal association between these adverse events and ABELCET is uncertain.[0m

[34mSOURCE: ABELCET label[0m
[34mEXTRACT_START_END: Cardiopulmonary: cardiac failure, pulmonary edema, shock, myocardial infarction[0m[34m...[0m[34m cardiomyopathy, pleural effusion, arrhythmias including ventricular fibrillation.[0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ABELCET increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if ABELCET increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that myocardial infarction has been reported as an adverse event in patients using ABELCET in open-label, uncontrolled clinical studies, but the causal association between [0m
[32mthese adverse events and ABELCET is uncertain."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ABELCET has been associated with reports of myocardial infarction as an adverse event; however, the causal relationship between ABELCET and myocardial infarction is not clearly [0m
[32mestablished. Therefore, it is not definitively known if ABELCET increases or decreases the risk of myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ABELCET increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if ABELCET increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that myocardial infarction has been reported as an adverse event in patients using ABELCET in open-label, uncontrolled clinical studies, but the causal association between [0m
[34mthese adverse events and ABELCET is uncertain."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ABELCET has been associated with reports of myocardial infarction as an adverse event; however, the causal relationship between ABELCET and myocardial infarction is not clearly [0m
[34mestablished. Therefore, it is not definitively known if ABELCET increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ABELCET increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if ABELCET increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that myocardial infarction has been reported as an adverse event in patients using ABELCET in open-label, uncontrolled clinical studies, but the causal association between [0m
[31mthese adverse events and ABELCET is uncertain.[0m
[31m        -----[0m
[31m        Final answer: ABELCET has been associated with reports of myocardial infarction as an adverse event; however, the causal relationship between ABELCET and myocardial infarction is not clearly [0m
[31mestablished. Therefore, it is not definitively known if ABELCET increases or decreases the risk of myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ABELCET[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mABELCET has been associated with reports of myocardial infarction as an adverse event; however, the causal relationship between ABELCET and myocardial infarction is not clearly established. Therefore,[0m
[32mit is not definitively known if ABELCET increases or decreases the risk of myocardial infarction.[0m
